Total Payments
$1.0M
2024 Payments
$106,976
Companies
16
Transactions
825
Medicare Patients
189
Medicare Billing
$18,512
Payment Breakdown by Category
Other$547,354 (53.1%)
Consulting$283,676 (27.5%)
Travel$97,089 (9.4%)
Research$61,409 (6.0%)
Education$29,197 (2.8%)
Food & Beverage$11,202 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $426,254 | 196 | 41.4% |
| Consulting Fee | $283,676 | 100 | 27.5% |
| Grant | $115,000 | 2 | 11.2% |
| Travel and Lodging | $97,089 | 254 | 9.4% |
| Unspecified | $61,409 | 22 | 6.0% |
| Education | $29,197 | 18 | 2.8% |
| Food and Beverage | $11,202 | 231 | 1.1% |
| Honoraria | $3,600 | 1 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,500 | 1 | 0.2% |
Payments by Type
General
$968,517
803 transactions
Research
$61,409
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $388,465 | 214 | $0 (2024) |
| UCB, Inc. | $160,095 | 288 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $107,727 | 89 | $0 (2024) |
| PFIZER INC. | $102,870 | 62 | $0 (2024) |
| Celgene Corporation | $55,958 | 33 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $50,190 | 23 | $0 (2024) |
| Eli Lilly and Company | $46,013 | 3 | $0 (2021) |
| Janssen Biotech, Inc. | $42,520 | 42 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $40,007 | 50 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $19,750 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $106,976 | 66 | ABBVIE INC. ($46,472) |
| 2023 | $113,937 | 31 | AbbVie Inc. ($71,187) |
| 2022 | $241,995 | 125 | ABBVIE INC. ($198,030) |
| 2021 | $115,733 | 47 | Eli Lilly and Company ($46,009) |
| 2020 | $44,454 | 26 | AbbVie Inc. ($11,400) |
| 2019 | $162,536 | 161 | Celgene Corporation ($41,087) |
| 2018 | $130,462 | 175 | UCB, Inc. ($64,610) |
| 2017 | $113,834 | 194 | UCB, Inc. ($82,266) |
All Payment Transactions
825 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,847.12 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $145.34 | General |
| Category: IMMUNOLOGY | ||||||
| 10/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $19,550.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Consulting Fee | Cash or cash equivalent | $8,362.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $66.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $51.09 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/09/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $33.45 | General |
| 08/14/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ETRASIMOD CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 07/22/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $1,102.16 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 07/19/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ETRASIMOD CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 07/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,950.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $439.45 | General |
| Category: Immunology | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $44.25 | General |
| Category: Immunology | ||||||
| 06/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $51.90 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $34.29 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $103.51 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: Immunology | ||||||
| 05/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $42.57 | General |
| Category: IMMUNOLOGY | ||||||
| 05/19/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Immunology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $146.28 | General |
| Category: Immunology | ||||||
| 05/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Immunology | ||||||
| 04/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $3,612.50 | General |
| Category: Immunology | ||||||
| 04/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.88 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN ADAPTIVE PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LY3471851 (NKTR 358) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $30,996 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $15,013 | 1 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,670 | 4 |
| Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from a Pharmacovigilance Safety Database | UCB, Inc. | $2,800 | 1 |
| Effects of Transient and Persistent Anti-Drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7 Year Study in Crohn's Disease | UCB, Inc. | $2,300 | 1 |
| Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database | UCB, Inc. | $840.00 | 1 |
| Perceptions of Healthcare Professionals Towards the Use of Anti-Tumor Necrosis Factor Biologics to Treat Moderate to Severe Plaque Psoriasis in Women of Childbearing Age | UCB, Inc. | $800.00 | 1 |
| Perceptions of Healthcare Professionals Towards the Use of Anti-Tumor Necrosis Factor Biologics to Treat Moderate to Severe Chronic Plaque Psoriasis in Women of Childbearing Age | UCB, Inc. | $420.00 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | Eli Lilly and Company | $3.65 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 18 | 18 | $4,680 | $1,453 |
| 2021 | 4 | 75 | 77 | $28,625 | $7,895 |
| 2020 | 6 | 96 | 99 | $36,235 | $9,165 |
Total Patients
189
Total Services
194
Medicare Billing
$18,512
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 18 | 18 | $4,680 | $1,453 | 31.0% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 17 | 17 | $11,985 | $2,561 | 21.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 31 | 31 | $7,905 | $2,507 | 31.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 14 | $4,760 | $1,519 | 31.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 15 | $3,975 | $1,308 | 32.9% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 17 | 18 | $12,510 | $2,464 | 19.7% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 25 | 25 | $6,250 | $2,073 | 33.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 18 | $6,390 | $1,991 | 31.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $4,355 | $1,452 | 33.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 14 | 14 | $6,510 | $1,134 | 17.4% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2020 | 11 | 11 | $220.00 | $50.57 | 23.0% |
About Dr. Anita Afzali, MD
Dr. Anita Afzali, MD is a Gastroenterology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932117074.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anita Afzali, MD has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $106,976 received in 2024. These payments were reported across 825 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($426,254).
As a Medicare-enrolled provider, Afzali has provided services to 189 Medicare beneficiaries, totaling 194 services with total Medicare billing of $18,512. Data is available for 3 years (2020–2022), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Cincinnati, OH
- Active Since 08/04/2006
- Last Updated 07/27/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1932117074
Products in Payments
- RINVOQ (Biological) $192,668
- SKYRIZI (Biological) $118,116
- XELJANZ (Drug) $77,844
- STELARA (Biological) $66,604
- Entyvio (Biological) $64,108
- Cimzia (Drug) $50,246
- Ozanimod (Drug) $41,110
- ENTYVIO (Biological) $36,549
- ZEPOSIA (Drug) $25,719
- VELSIPITY (Drug) $18,890
- HUMIRA (Biological) $12,148
- TREMFYA (Drug) $11,221
- Humira (Biological) $7,022
- Tremfya (Drug) $6,528
- Resolution Clip (Device) $250.07
- TALTZ (Drug) $24.61
- OMVOH (Drug) $18.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Cincinnati
Dr. Allan Peck, M.d, M.D
Gastroenterology — Payments: $481,678
Gastroenterology $481,678
Kara De Felice, M.d, M.D
Gastroenterology — Payments: $472,231
Gastroenterology $472,231
Dr. Ravi Ravinuthala, M.d, M.D
Gastroenterology — Payments: $401,840
Gastroenterology $401,840
Luis Lara, Md, MD
Gastroenterology — Payments: $174,958
Gastroenterology $174,958
Dr. Lisa Lestina, M.d, M.D
Gastroenterology — Payments: $163,406
Gastroenterology $163,406
Robert Isfort, M.d, M.D
Gastroenterology — Payments: $121,512
Gastroenterology $121,512